MoneyWorks4Me

Glenmark to introduce higher strength of FabiFlu

06 Aug 2020 Evaluate
Glenmark Pharmaceuticals is going to introduce a 400 mg version of oral antiviral FabiFlu, for the treatment of mild to moderate COVID-19 in India. The higher strength will improve patient compliance and experience, by effectively reducing the number of tablets that patients require per day.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Peers
Company Name CMP
Sun Pharma. Inds. 1757.75
Dr. Reddys Labs. 1169.60
Cipla 1298.20
Lupin 1966.60
Zydus Lifesciences 1114.85
View more..